Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults

In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF, compared with semaglutide, with a similar safety profile.

Authors

Institutions

Publication Details

Journal
Diabetes Obesity and Metabolism
Published
2026-03-27
DOI
https://doi.org/10.1111/dom.70721
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults

Nicholas Wettersten, Mai Katsura, K Tanabe, Yu Horiuchi
Diabetes Obesity and Metabolism
Diabetes Treatment and Management
article

Real‐World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non‐Diabetic Adults

Nicholas Wettersten, Mai Katsura, K Tanabe, Yu Horiuchi
article en

Abstract

In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF, compared with semaglutide, with a similar safety profile.

Diabetes Obesity and Metabolism
University of San Diego (US), University of California San Diego (US), VA San Diego Healthcare System (US), Mitsui Memorial Hospital (JP)
Good health and well-being
Openalex Percentile: Top 7%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.